Ketamine for Adolescent Suicidality
Mental Health & Behavioral Research
What is the purpose of this trial?
The purpose of this study is to determine if intravenous ketamine reduces suicidal thinking compared to an active placebo (midazolam) in adolescents who have treatment resistant depression and a recent history of a suicide event (defined as a suicide attempt, emergency room evaluation for suicidal thinking, or a transition to inpatient care for suicidality in the past 120 days).
The primary objective of this study is to determine whether ketamine reduces suicidal ideation (as measured via the C-SSRS, recent ideation scale) relative to an active control, midazolam, 48-hours after first administration in adolescents with TRD at high suicide risk.
- Ages13 years - 17 years
- Trial withNational Institutes of Health (NIH)
- Start Date01/21/2022
- End Date12/31/2024
- Last Updated01/28/2022
- Study HIC#2000029003